» Articles » PMID: 32928939

Untargeted Metabolomics Yields Insight into ALS Disease Mechanisms

Overview
Date 2020 Sep 15
PMID 32928939
Citations 38
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To identify dysregulated metabolic pathways in amyotrophic lateral sclerosis (ALS) versus control participants through untargeted metabolomics.

Methods: Untargeted metabolomics was performed on plasma from ALS participants (n=125) around 6.8 months after diagnosis and healthy controls (n=71). Individual differential metabolites in ALS cases versus controls were assessed by Wilcoxon rank-sum tests, adjusted logistic regression and partial least squares-discriminant analysis (PLS-DA), while group lasso explored sub-pathway-level differences. Adjustment parameters included sex, age and body mass index (BMI). Metabolomics pathway enrichment analysis was performed on metabolites selected by the above methods. Finally, machine learning classification algorithms applied to group lasso-selected metabolites were evaluated for classifying case status.

Results: There were no group differences in sex, age and BMI. Significant metabolites selected were 303 by Wilcoxon, 300 by logistic regression, 295 by PLS-DA and 259 by group lasso, corresponding to 11, 13, 12 and 22 enriched sub-pathways, respectively. 'Benzoate metabolism', 'ceramides', 'creatine metabolism', 'fatty acid metabolism (acyl carnitine, polyunsaturated)' and 'hexosylceramides' sub-pathways were enriched by all methods, and 'sphingomyelins' by all but Wilcoxon, indicating these pathways significantly associate with ALS. Finally, machine learning prediction of ALS cases using group lasso-selected metabolites achieved the best performance by regularised logistic regression with elastic net regularisation, with an area under the curve of 0.98 and specificity of 83%.

Conclusion: In our analysis, ALS led to significant metabolic pathway alterations, which had correlations to known ALS pathomechanisms in the basic and clinical literature, and may represent important targets for future ALS therapeutics.

Citing Articles

Gut microbiota immune cross-talk in amyotrophic lateral sclerosis.

Kaul M, Mukherjee D, Weiner H, Cox L Neurotherapeutics. 2024; 21(6):e00469.

PMID: 39510899 PMC: 11585889. DOI: 10.1016/j.neurot.2024.e00469.


Metabolomics Unveils Disrupted Pathways in Parkinson's Disease: Toward Biomarker-Based Diagnosis.

Santos W, Katchborian-Neto A, Viana G, Ferreira M, Martins L, Vale T ACS Chem Neurosci. 2024; 15(17):3168-3180.

PMID: 39177430 PMC: 11378289. DOI: 10.1021/acschemneuro.4c00355.


Disturbances in Muscle Energy Metabolism in Patients with Amyotrophic Lateral Sclerosis.

Parvanovova P, Hnilicova P, Kolisek M, Tatarkova Z, Halasova E, Kurca E Metabolites. 2024; 14(7).

PMID: 39057679 PMC: 11278632. DOI: 10.3390/metabo14070356.


Associations of neighborhood sociodemographic environment with mortality and circulating metabolites among low-income black and white adults living in the southeastern United States.

Deng K, Xu M, Sahinoz M, Cai Q, Shrubsole M, Lipworth L BMC Med. 2024; 22(1):249.

PMID: 38886716 PMC: 11184804. DOI: 10.1186/s12916-024-03452-6.


Metal mixtures associate with higher amyotrophic lateral sclerosis risk and mortality independent of genetic risk and correlate to self-reported exposures: a case-control study.

Jang D, Dou J, Koubek E, Teener S, Zhao L, Bakulski K medRxiv. 2024; .

PMID: 38464233 PMC: 10925361. DOI: 10.1101/2024.02.27.24303143.


References
1.
Al-Chalabi A, Hardiman O . The epidemiology of ALS: a conspiracy of genes, environment and time. Nat Rev Neurol. 2013; 9(11):617-28. DOI: 10.1038/nrneurol.2013.203. View

2.
Dodge J, Treleaven C, Pacheco J, Cooper S, Bao C, Abraham M . Glycosphingolipids are modulators of disease pathogenesis in amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A. 2015; 112(26):8100-5. PMC: 4491749. DOI: 10.1073/pnas.1508767112. View

3.
DAmico E, Factor-Litvak P, Santella R, Mitsumoto H . Clinical perspective on oxidative stress in sporadic amyotrophic lateral sclerosis. Free Radic Biol Med. 2013; 65:509-527. PMC: 3859834. DOI: 10.1016/j.freeradbiomed.2013.06.029. View

4.
Britto Chaves-Filho A, Pinto I, Dantas L, Machado Xavier A, Inague A, Faria R . Alterations in lipid metabolism of spinal cord linked to amyotrophic lateral sclerosis. Sci Rep. 2019; 9(1):11642. PMC: 6691112. DOI: 10.1038/s41598-019-48059-7. View

5.
Su F, Goutman S, Chernyak S, Mukherjee B, Callaghan B, Batterman S . Association of Environmental Toxins With Amyotrophic Lateral Sclerosis. JAMA Neurol. 2016; 73(7):803-11. PMC: 5032145. DOI: 10.1001/jamaneurol.2016.0594. View